

OREGON

# Medical office update



OCTOBER 2021

## In this issue

- Emerging Health
- COVID-19 vaccine
- Strive Health
- Medical record project – Transitions of Care
- Reimbursement Policy updates
- Medical Necessity Criteria updates

## Join our email list

[Join our email list](#) in order to begin receiving bi-monthly newsletters, as well as occasional electronic communications.

## New Partnership announcement for Infusion and Enteral Therapies

We are excited to announce a new partnership between Emerging Health and Moda Health! Emerging Health is a new, locally owned, and operated home infusion and ambulatory infusion center located in Southwest Portland.

Emerging Health offers the following services and therapies:

- **Home Infusion:** Patients can receive treatment in the comfort of their homes. Personalized care options give patients freedom that fits their lifestyle.
- **Ambulatory Infusion Center (AIC):** The ambulatory facility in Southwest Portland provides a safe and supportive setting for patients and caregivers. Patients receive care in a private infusion suite. They also have a suite designed just for children.
- **Enteral Therapy:** Local 1:1 education, monitoring, and assessments from board-certified nutrition support clinicians for tube-fed patients.

## The Emerging Health Difference

Emerging Health strives to exceed expectations and ensure patients and their caregivers have positive and thoughtfully coordinated experiences. They view their service as an extension of the care you and your staff provide.

- Emerging Health ensures safety, comfort, and convenience by offering treatment in one of their private infusion suites or in the patient's home
- Their local, experienced pharmacy team prepares and packs all medication, supplies and equipment
- Patients receive personalized care plans that incorporate all aspects of their lives
- Their team uses advanced technologies and medical innovations to improve the experience and outcomes of their patients
- You get live, local support to coordinate intake, authorization and billing for Moda Health plan members

**To learn more, place a referral or arrange for a tour of our facility, please call 877-290-2040.**

## COVID Vaccines

As the global COVID-19 pandemic progresses, the vaccine landscape continues to be studied and recommendations evolve. The CDC recommends preventing the COVID-19 virus and variants by one of three available vaccines: the Pfizer-BioNTech vaccine, COMIRNATY® (granted full FDA approval), Moderna (authorized by the FDA) and Janssen (authorized by the FDA<sup>1</sup>).

The recommendations are summarized below:

### **1. Pfizer-BioNTech COVID-19 Vaccine (COMIRNATY®)<sup>2,3</sup>**

- FDA grants full approval to COMIRNATY as a two-dose series in persons 16 years of age and older effective Sept. 23, 2021

- The Emergency Use Authorization (EUA) remains in place for the following populations:

- Two dose series in persons 12 to 15 years of age
- Third dose administered at least 28 days following the second dose for persons 12 years of age and older with a solid organ transplant or who are diagnosed with other conditions with an equivalent level of immunocompromise

### **2. Moderna COVID-19 Vaccine<sup>4</sup>**

Available under EUA authorization for the following indications:

- Two-dose series in persons 18 years of age and older

- Third dose administered at least 28 days following the second dose for persons 18 years of age and older with solid organ transplant or who are diagnosed with other conditions with an equivalent level of immunocompromise

### 3. Janssen (J&J) COVID-19 Vaccine<sup>5</sup>

Available under EUA authorization for the following indications:

- Single-dose series in persons 18 years of age and older

When a third dose is indicated for those who are moderately to severely immunocompromised, the mRNA vaccine given should match the vaccine used in the initial two-dose series. If you cannot get the product, you can use the vaccine from the other manufacturer.

At the time of writing, an FDA advisory panel recommends a booster dose of the Pfizer-BioNTech COVID-19 vaccine for people 65 years and older, those at high risk for severe COVID infection, and for healthcare professionals or others at high risk for occupational exposure. Adoption of this recommendation by the FDA is expected soon.<sup>6</sup> Additionally, Pfizer stated their intention to submit data to the FDA by the end of September showing vaccine efficacy in children age 5 to 11 years.<sup>7</sup> It should be noted that regardless of booster doses, data shows that the original vaccine series remains highly effective against the spread of virus and prevention of serious illness, hospitalization and/or death from COVID-19.

As flu season approaches, vaccination with both the COVID-19 and flu vaccines should be pursued. These vaccines can be administered at the same time.

#### References

1. Centers for Disease Control and Prevention. COVID-19 ACIP Vaccine Recommendations. last updated 30<sup>th</sup> August 2021. Accessed from: <https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html>
2. U.S. Food and Drug Administration. Pfizer-BionTech COVID-19 Vaccine EUA Letter of Authorization. 23 August 2021. Accessed from: <https://www.fda.gov/media/150386/download>
3. U.S. Food and Drug Administration. COMIRNATY Approval Letter. 23 August 2021. Accessed from: <https://www.fda.gov/media/151710/download>.
4. U.S. Food and Drug Administration. Moderna COVID-19 Vaccine EUA Letter of Authorization. 12 August 2021. Accessed from: <https://www.fda.gov/media/144636/download>
5. U.S. Food and Drug Administration. Janssen COVID-19 Vaccine EUA Letter of Authorization. 10 June 2021. Accessed from: <https://www.fda.gov/media/146303/download>
6. AMCP Daily Dose. FDA Panel Voted To Recommend Coronavirus Boosters for Older Adults And Individuals At Risk Of Serious Illness. 17 September 2021. Accessed from: <https://amcp.bulletinhealthcare.com/?tokenid=d9838216n7465iq72255172272465iq7225kj941&dt=20210921&d=2021-09-20&a=S1>
7. Lovelace B. Pfizer CEO says Covid vaccine data for kids under age 5 may come in late October. 14 September 2021. Accessed from: <https://www.cnbc.com/2021/09/14/pfizers-covid-vaccine-data-for-kids-under-age-5-may-come-in-late-october-ceo-says-.html>

## Compassionate kidney care

Moda Health has partnered with Strive Health to provide members with chronic kidney disease stages 3, 4 and 5, and end-stage renal disease will receive kidney disease care coordination services. The Strive Health proven care model intervenes early to help slow kidney disease progression, reduce dialysis crashes, increase home dialysis adoption and reduce hospitalizations.

Our partnership with Strive Health offers members:

- 24-hour-a-day access to a kind and knowledgeable team of Kidney Heroes™
- Convenient scheduling options, including telehealth and home visits

- Access to experts in kidney care who want you to have a great experience
- Care coordination with the member’s healthcare providers
- Coaching for diet, exercise and stress management

If interested in learning more about Strive Health, please contact [providerrelations@modahealth.com](mailto:providerrelations@modahealth.com).

## Transitions of Care (TRC) medical record review project

We’ve partnered with KDJ Consultants to assist with off-season chart retrievals for the Transitions of Care measure. We encourage you to allow remote access to minimize Covid-19 exposure and reduce administrative burden.

To establish, please contact [HEDIS@modahealth.com](mailto:HEDIS@modahealth.com) or call 503-412-4001. We greatly appreciate your assistance with this project.

## Reimbursement Policy Updates

Policy	Reason for review	Summary of update
<b>Reviewed in August, 2021</b>		
RPM013, “Modifiers 80, 81, 82 and AS - Assistant At Surgery”	Annual review	<ul style="list-style-type: none"> <li>• Removed references to EOCCO, as we now have more than one Medicaid plan</li> <li>• Scope section: Added Summit Health plan</li> <li>• Converted to outline format</li> <li>• Section D, updated Medicare Advantage and Medicaid rates</li> <li>• Acronym table: Added 15 listings</li> <li>• Important statement section wording updated</li> <li>• Minor grammar and format updates</li> </ul>
RPM022, “Modifier 51 - Multiple Procedure Fee Reductions”	Annual review	<ul style="list-style-type: none"> <li>• Removed references to EOCCO, as we now have more than one Medicaid plan</li> <li>• Scope section: Added Summit Health plan</li> <li>• Added section A.3.</li> <li>• Section B.3, C and D wording simplified to “Effective July 1, 2018...”</li> <li>• Section C.4 and D.4 added to provide instructions for questions about guidelines prior to July 1, 2018</li> <li>• Section C and D updated to reflect that CMS, ASC and OPps multiple procedure indicators are applied</li> <li>• Background section moved to follow References and Resources section</li> <li>• Important statement section wording updated</li> </ul>
RPM056, “Medically Unlikely Edits (MUEs)”	Annual review	<ul style="list-style-type: none"> <li>• Removed references to EOCCO, as we now have more than one Medicaid plan</li> <li>• Scope section: Added Summit Health plan</li> <li>• Section A.1.a and c: Added clarification that ASC claims on CMS1500 claims are subject to Professional MUEs, but hospital-based ASC claims on UB/CMS1450 claims are subject to OPps MUEs</li> </ul>

- Acronym table added multiple listings
- Important statement section wording updated
- Minor format updates

RPM058, "Behavioral Health Case Management and Care Coordination" Annual review

- Sections B.1.d and B.2.d: Added H0040 as eligible for licensed behavioral health professionals (B.1.d.) and Qualified Mental Health Professionals (B.2.d.)
- Section D: H0040 reason column updated with date information
- Minor format updates

**Note:** There are no policies that have been reviewed during September for this newsletter. Review is in progress on a number of policies, but no updates have been completed, approved, and posted.

## Medical criteria changes July/Aug 2021

Medical criteria	July medical criteria summary	Pharmacy/medical
<b>Panniculectomy (abdominal skin/fat surgery)</b>	<p><b>Introduction:</b> This is annual review.</p> <p><b>Criteria changes:</b> Title updated to "Panniculectomy (abdominal skin/fat surgery) to align with policy indications</p>	Medical
<b>Endoscopic procedure for treatment of GERD</b>	<p><b>Introduction:</b> This is annual review.</p> <p><b>Criteria changes:</b> No content changes</p>	Medical
<b>Genetic testing</b>	<p><b>Introduction:</b> This is an annual review.</p> <p><b>Criteria changes:</b> Expanded the indications for breast cancer index coverage. Added coverage requirements for risk stratification for uveal melanoma.</p>	Medical
<b>Mobile outpatient cardiac telemetry</b>	<p><b>Introduction:</b> This is an annual review.</p> <p><b>Criteria changes:</b> No content changes</p>	Medical
<b>Negative pressure wound therapy (vacuum-assisted wound closure)</b>	<p><b>Introduction:</b> This is an annual review:</p> <p><b>Criteria changes:</b> No content changes</p>	Medical
<b>Serum antibodies for diagnosis of inflammatory bowel disease</b>	<p><b>Introduction:</b> This is an annual review:</p> <p><b>Criteria changes:</b> No content changes</p>	Medical
<b>Air ambulance transport</b>	<p><b>Introduction:</b> This is an annual review.</p> <p><b>Criteria changes:</b> Language update, "scheduled" non-emergent air transport</p>	Medical
<b>Medical nutrition therapy/nutritional counseling</b>	<p><b>Introduction:</b> This is an annual review/update.</p> <p><b>Criteria changes:</b> Nutritional therapy criteria for eating disorders folded into this criteria set. Changed criteria for eating disorders so that the diagnosis alone is sufficient to satisfy criteria. Retire separate policy BHC 0013.</p>	Medical

Medical criteria	August medical criteria summary	Pharmacy/medical
<b>AFO-KAFO_HKAFO</b>	<b>Introduction:</b> This is annual review. <b>Criteria changes:</b> No changes	Medical
<b>Cranial orthotics</b>	<b>Introduction:</b> This is annual review. <b>Criteria changes:</b> No changes	Medical
<b>Factor V Leiden Thrombophilia-F5 Gene</b>	<b>Introduction:</b> This is annual review. <b>Criteria changes:</b> No changes	Medical
<b>Knee cartilage transplants</b>	<b>Introduction:</b> This is annual review. <b>Criteria changes:</b> No changes	Medical
<b>Obstructive sleep apnea (OSA) non-surgical treatment</b>	<b>Introduction:</b> This is annual review. <b>Criteria changes:</b> No changes	Medical
<b>Push-rim activated power assist device</b>	<b>Introduction:</b> This is annual review. <b>Criteria changes:</b> No changes	Medical
<b>Therapeutic drug monitoring (TDM)</b>	<b>Introduction:</b> This is annual review. <b>Criteria changes:</b> No changes	Medical
<b>Upper extremity orthoses</b>	<b>Introduction:</b> This is annual review. <b>Criteria changes:</b> No changes	Medical

## Contact us

### Moda Medical Customer Service

For claims review, adjustment requests and/or billing policies, please call 888-217-2363 or email [medical@modahealth.com](mailto:medical@modahealth.com).

### Moda Provider Relations

For escalated claim inquiries, contract interpretation, educational opportunities or onsite visit requests please email [providerrelations@modahealth.com](mailto:providerrelations@modahealth.com)

### Provider Updates

For provider demographic and address updates, please email [providerupdates@modahealth.com](mailto:providerupdates@modahealth.com).

### Credentialing Department

For credentialing questions and requests, please email [credentialing@modahealth.com](mailto:credentialing@modahealth.com).



503-228-6554 | [medical@modahealth.com](mailto:medical@modahealth.com) | [modahealth.com](http://modahealth.com)

Copyright © 2021. All Rights Reserved.